Roundtable: April 24, 2025

Due to the HHS pause, we pushed the date of this Roundtable back to April 24.

We are facilitating multi-stakeholder dialogue, accelerating transformative changes, collaboratively identifying the barriers obstructing progress, and charting the best path forward in obesity drug development. With over 40% of adults in the United States classified as obese in 2020 according to CDC data, both the urgency and momentum behind obesity drug development have intensified in recent years. It's important to recognize that the current obesity drug development framework not only addresses weight loss, but also targets the treatment or prevention of comorbidities associated with obesity. Despite some existing regulatory guidelines, medical product development in the obesity space encounters unique challenges that require our collective attention to drive further progress.

Our goal is to shape the future of obesity drug development by convening diverse participants and soliciting viewpoints and ideas from executives and experts across academia, industry, regulators, nonprofit organizations and patient communities throughout this interactive and problem-solving roundtable. Together, we’ll unravel the potential and address the hurdles of this dynamic frontier in healthcare.

Interested in attending? Please fill out our Interest Form to get started!